Business Summary
- Service: discovery, identification and selection of new therapeutic targets in oncology;
- Biotech: development of a portfolio of therapeutic and diagnostic projects alone or through partnerships;
- Artificial Intelligence: development of a platform for selecting new therapeutic targets in oncology.
60.3% of sales are abroad.
Number of employees: 236
Managers
Managers | Title | Age | Since |
---|---|---|---|
Fabrice Viviani
CEO | Chief Executive Officer | - | - |
Arnaud Lafforgue
DFI | Director of Finance/CFO | - | 01/18/01 |
Stéphane Gerart
CTO | Chief Tech/Sci/R&D Officer | - | 01/20/01 |
Jan Hoflack
CTO | Chief Tech/Sci/R&D Officer | 63 | 01/09/01 |
Karine Lignel
BRD | Director/Board Member | 55 | 14/08/14 |
General Counsel | - | 01/21/01 | |
Thierry Billoué
HRO | Human Resources Officer | - | 01/17/01 |
62 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kamel Besseghir
BRD | Director/Board Member | 75 | 03/14/03 |
62 | - | ||
Karine Lignel
BRD | Director/Board Member | 55 | 14/08/14 |
Fabrice Viviani
CEO | Chief Executive Officer | - | - |
Aline Aubertin
BRD | Director/Board Member | - | 24/21/24 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 6,848,412 | 730,880 ( 10.67 %) | 0 | 10.67 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Pharmaceuticals: Major
|
Sector
1st Jan change | Capi. | |
---|---|---|
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |